Rabbit Polyclonal NFkB p100/NFKB2 phospho S865 antibody. Suitable for IP, WB and reacts with Human, Mouse samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human NFKB2 phospho S865 aa 800 to C-terminus.
pH: 6.8 - 7.4
Preservative: 0.09% Sodium azide
Constituents: Tris buffered saline, 0.1% BSA
IP | WB | |
---|---|---|
Human | Tested | Tested |
Mouse | Expected | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 2.00000-10.00000 µg/mg of lysate | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/2000.00000 - 1/10000.00000 | Notes - |
Species Human | Dilution info 1/2000.00000 - 1/10000.00000 | Notes - |
Select an associated product type
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer.
LYT10, NFKB2, Nuclear factor NF-kappa-B p100 subunit, DNA-binding factor KBF2, H2TF1, Lymphocyte translocation chromosome 10 protein, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, Oncogene Lyt-10, Lyt10
Rabbit Polyclonal NFkB p100/NFKB2 phospho S865 antibody. Suitable for IP, WB and reacts with Human, Mouse samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human NFKB2 phospho S865 aa 800 to C-terminus.
pH: 6.8 - 7.4
Preservative: 0.09% Sodium azide
Constituents: Tris buffered saline, 0.1% BSA
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lysates prepared in NETN buffer.
All lanes: Western blot - Anti-NFkB p100/NFKB2 antibody (ab264236) at 0.1 µg/mL
Lane 1: HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 50 µg
Lane 2: HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 50 µg
Lane 3: Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate at 50 µg
Lane 4: TCMK-1 (mouse kidney epithelial cell line) whole cell lysate at 50 µg
Lane 5: NIH/3T3 (mouse embryo fibroblast cell line) whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 97 kDa
Exposure time: 3min
NFkB p100 / p52 was immunoprecipitated from HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate (0.5 or 1.0
mg per IP reaction; 20% of IP loaded) using ab264236 at 6 μg per reaction. Western blot was performed on the immunoprecipitates using ab264236 at 1 μg/ml.
Lane 1: ab264236 IP in HeLa whole cell lysate.
Lane 2: Control IgG IP in Hela whole cell lysate.
Exposure time: 3 minutes.
Lysates prepared in NETN buffer.
All lanes: Immunoprecipitation - Anti-NFkB p100/NFKB2 antibody (ab264236)
Predicted band size: 97 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com